

Cytosorbents Corp
Form 8-K
June 08, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): June 7, 2016

CYTOSORBENTS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

000-51038

(Commission File Number)

98-0373793

(I.R.S. Employer Identification No.)

7 Deer Park Drive, Suite K,

Monmouth Junction, New Jersey 08852

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (732) 329-8885

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders

CytoSorbents Corporation (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 7, 2016. At the Annual Meeting, the following matters were submitted to a vote of stockholders:

1. The election of five (5) directors to serve until the Company’s 2017 Annual Meeting of Stockholders, or until their respective successors shall have been duly elected and qualified; and
2. The ratification of the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the year ending December 31, 2016.

At the close of business on April 13, 2016, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 25,410,101 shares of the Company’s Common Stock outstanding and entitled to vote at the Annual Meeting. The holders of 20,353,135 shares of the Company’s Common Stock were represented in person or by proxy at the Annual Meeting, constituting a quorum.

At the Annual Meeting, the five directors were elected, and the other proposal submitted to stockholders was approved.

Proposal No. 1 — Election of Directors

The vote with respect to the election of directors was as follows:

Nominees	For	Withheld	Broker Non-Votes
Phillip P. Chan	9,553,100	100,241	10,699,794
Al W. Kraus	8,896,030	757,311	10,699,794
Edward R. Jones	9,507,083	146,258	10,699,794
Michael G. Bator	9,534,614	118,727	10,699,794
Alan D. Sobel	9,533,036	120,305	10,699,794

Proposal No. 2 — Ratification of the Appointment of Independent Registered Public Accounting Firm

Edgar Filing: Cytosorbents Corp - Form 8-K

The vote with respect to the ratification of the appointment of WithumSmith+Brown PC as the Company's independent registered public accounting firm for the year ending December 31, 2016 was as follows:

For	Against	Abstain
20,271,312	54,304	27,514

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 8, 2016 CYTOSORBENTS
CORPORATION

By: /s/ Dr. Phillip P. Chan
Name: Dr. Phillip P. Chan
President and
Title: Chief Executive Officer